GREY:ATBPF - Post by User
Post by
cpt2010on May 25, 2020 7:56pm
388 Views
Post# 31071030
Why I am bullish going forward
Why I am bullish going forwardI added today, as I believe we will soon blast into 75c. ATE remains my biggest position, with an average of around 65c. I have read studies that John had done with NO, and I believe H2S has a big opportunity going forward. John probably has learned what the FDA wants, and believes that ATb346 has bigger potential. Here is why I am bullish.
A) We already know naproxen works, so adding h2s is going to be even better in this phase 2b data coming out. I expect data around June 15, I do not expect any more delays.
B) Naproxen + NO was denied, as the dosage they used in the study was very high. John/Dan were smart testing the low dosage as this would mean even less harmful effects for ulcers, BP etc.
C) Valuation around $200m for a potential blockbuster is too cheap. After Phase 2, I expect a $300m valuation. I also expect a secondary of around $40m in 1-2 weeks post data. They need money to continue their work on atb 340 and 352.
D) Partnerships will come, but maybe in a few months as they continue to negotiate. Remember that NO+Naproxen has AZN as a partner, so I am sure we will see Bayer or someone else get involved.
E) 200-300m valuation is cheap, there could be a potential buyer buying them in late 2020 or 2021.
F) I see low risks at this price. I expect v positive data, and if the 150mg dose works well, expect a big jump in price.
G) Insiders own 19% of the company, that is positive.
H) Over 1$, I expect a nasdaq listing into 2020, or 2021.
I) My target is around $1 to $1.1 apost data, with a run into 2$ into end 2020.
Good luck to all